Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

NCT06979375 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06979375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06979375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2025
Completion date
January 23, 2028
Enrollment
200 (estimated)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure